An international team of researchers revealed the effect of combining Rapamycin and Tarmetinib on the laboratory mice, indicating that they had overcame the life of animals by about 30%.
It was found that this composed treatment improves the health of mice at an advanced age, as it reduces the extent of chronic inflammation in the brain and other tissues, and slows down the appearance of cancer. Chronic inflammation is a process where the immune system continues to pump white blood cells and send chemical messages that prolong inflammation.
The study was conducted by researchers from the Department of Biological Mechanisms for Kehkha, the Max Planck Institute for Aging Biology, Cologne, Germany and the Institute of Health and Genetic Engineering, London University College, London, UK, and its results were published in the “Nicure Age” magazine on May 28, and the American Journal of New Yazweik was written about.
“We do not expect a similar lengthening in the ages of humans as we found in mice.” “We hope that the medicines on which our research will be helped by people to stay in good health and without diseases longer in the advanced stages of life,” she added.
Rapamisin and tramstinib are used to treat cancer, as they work on different points in the path of signals that organize cell growth, metabolism and age. Rapamicin was approved by the US Food and Drug Administration to treat patients after kidney transplantation and to treat a number of cancers, and Rapamisin showed an effective and proven preventive effect against aging.
Tramitnib belongs to a category of medicines known as quinaz inhibitors. It works by preventing an abnormal protein activity that sends signals to the division of cancer cells, which helps to stop the spread of these cells. Tramitinib is used alone or with other medications to treat certain types of melanoma (a type of skin cancer).
Effects on genes
The team found that combining the two medicines is more effective than using either alone, although they work in the same way. Specifically, it was found that tramitinib alone increases the age of mice by 5-10%, while Rapamiesin alone increases by 15-20%.
The researchers say this mixture causes new effects on genetic activity, which exceeds that expected from just increasing the dose. After their initial studies are completed, researchers are now determining the optimum dose of tramitinib to prolong age while maintaining the minimum unwanted side effects.
“Tramitinib, especially with Rapamisin, is a good candidate for testing in clinical trials (on humans) as a aging factor. We hope that others will benefit from our results. Our focus is on improving the use of tramitinib in animal models,” said Sebastian Gronki, a biologist and author of the study of the Max Planck Institute for Aging Biology in Cologne, Germany.
“Conducting more research on humans in the coming years will help us to clarify how people benefit from these drugs, and who may benefit from them,” Bartridge concluded.